Patents Assigned to Asahi Kasei Pharma Corporation
-
Publication number: 20240025893Abstract: A compound represented by the general formula (1) or a salt thereof, which has a superior IRAK-4 inhibitory activity, and is useful as active ingredients of medicaments for prophylactic treatment and/or therapeutic treatment of diseases relating to IRAK-4 inhibition.Type: ApplicationFiled: September 30, 2020Publication date: January 25, 2024Applicants: Asahi Kasei Pharma Corporation, Vernalis (R&D) LimitedInventors: Koichiro ARAI, Kenichiro TAKABA, Masakazu ATOBE, Misato TAKASHIMA, Naomi AONO, Andrew John POTTER, Daniel Paul MADDOX
-
Publication number: 20230357271Abstract: A compound represented by the general formula (1) or a salt thereof, which has a superior IRAK-4 inhibitory activity, and is useful as active ingredients of medicaments for prophylactic treatment and/or therapeutic treatment of diseases relating to IRAK-4 inhibition.Type: ApplicationFiled: September 30, 2020Publication date: November 9, 2023Applicants: Asahi Kasei Pharma Corporation, Vernalis (R&D) LimitedInventors: Takahiko ITO, Misato TAKASHIMA, Masakazu ATOBE, Koichiro ARAI, Tomohisa TOYAMA, Yu YOSHII, Andrew John POTTER, Daniel Paul MADDOX, Stuart RAY, Nicolas FOLOPPE
-
Publication number: 20230125968Abstract: The present invention addresses the problem of providing a method for producing nicotinamide mononucleotide, that produces nicotinamide mononucleotide using a single enzyme and using nucleoside monophosphate, pyrophosphate, and nicotinamide as starting materials. This problem is solved by a nicotinamide mononucleotide production method that includes at least the following steps 1) and 2): 1) a first step of producing phosphoribosyl diphosphate by the action of substantially one enzyme on nucleoside monophosphate and pyrophosphate; and 2) a second step of producing nicotinamide mononucleotide by the action of only substantially the aforementioned one enzyme on nicotinamide and the phosphoribosyl diphosphate that is the product of the first step.Type: ApplicationFiled: October 26, 2022Publication date: April 27, 2023Applicant: Asahi Kasei Pharma CorporationInventors: Takeshi MATSUOKA, Tatsuya HIRATA, Masaru YAMAKOSHI
-
Patent number: 11439633Abstract: The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.Type: GrantFiled: December 4, 2020Date of Patent: September 13, 2022Assignees: RaQualia Pharma Inc., Asahi Kasei Pharma CorporationInventors: Yoshimasa Arano, Kazuki Toyoshima, Toshihiko Sone, Koki Matsubara
-
Patent number: 11077100Abstract: The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.Type: GrantFiled: March 13, 2018Date of Patent: August 3, 2021Assignees: RaQualia Pharma Inc., Asahi Kasei Pharma CorporationInventors: Hirohide Noguchi, Yoshimasa Arano, Kazuo Ando, Kazuki Toyoshima, Toshihiko Sone
-
Publication number: 20210188837Abstract: A novel compound represented by the following general formula (1), or a salt thereof, which has a superior EP4 receptor agonist activity, and a medicament containing the compound or a salt thereof as an active ingredient, which can be used for promotion of osteogenesis, therapeutic treatment and/or promotion of healing of fracture and the like.Type: ApplicationFiled: March 4, 2021Publication date: June 24, 2021Applicant: Asahi Kasei Pharma CorporationInventors: Daisuke SHIKANAI, Noriko ISHIGURO, Osamu OMORI
-
Publication number: 20210085667Abstract: The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.Type: ApplicationFiled: December 4, 2020Publication date: March 25, 2021Applicants: RaQualia Pharma Inc., Asahi Kasei Pharma CorporationInventors: Hirohide NOGUCHI, Yoshimasa ARANO, Kazuo ANDO, Kazuki TOYOSHIMA, Toshihiko SONE, Koki MATSUBARA
-
Publication number: 20200405706Abstract: The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.Type: ApplicationFiled: March 13, 2018Publication date: December 31, 2020Applicants: RaQualia Pharma Inc., Asahi Kasei Pharma CorporationInventors: Hirohide NOGUCHI, Yoshimasa ARANO, Kazuo ANDO, Kazuki TOYOSHIMA, Toshihiko SONE, Koki MATSUBARA
-
Publication number: 20200347046Abstract: A novel compound represented by the following general formula (1), or a salt thereof, which has a superior EP4 receptor agonist activity, and a medicament containing the compound or a salt thereof as an active ingredient, which can be used for promotion of osteogenesis, therapeutic treatment and/or promotion of healing of fracture and the like.Type: ApplicationFiled: December 25, 2018Publication date: November 5, 2020Applicant: Asahi Kasei Pharma CorporationInventors: Daisuke SHIKANAI, Noriko ISHIGURO, Osamu OMORI
-
Publication number: 20200101139Abstract: An object of the present invention is to provide an effective and safe medicament having effects for mitigating conditions and/or suppressing onset of a peripheral neuropathy induced by administration of an anti-malignant tumor agent, oxaliplatin, in a human cancer patient receiving an anti-malignant tumor treatment with oxaliplatin. There is provided a medicament for mitigating conditions and/or suppressing onset of a peripheral neuropathy induced by oxaliplatin in an anti-malignant tumor treatment consisting of repetition of a single cycle comprising intravenous administration of oxaliplatin to a human cancer patient and following drug withdrawal, which contains thrombomodulin for intravenously administering 0.06 mg/kg of thrombomodulin once per said single cycle of the treatment on the first day of each said cycle as an active ingredient.Type: ApplicationFiled: October 18, 2019Publication date: April 2, 2020Applicant: Asahi Kasei Pharma CorporationInventors: Takumi SAKAI, Genichi KUSAKAWA, Yugo UCHIDA
-
Patent number: 9555080Abstract: A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient.Type: GrantFiled: August 2, 2016Date of Patent: January 31, 2017Assignee: Asahi Kasei Pharma CorporationInventors: Kazuhisa Tsuruta, Yoshikazu Aoki, Yutaka Osawa, Inder Kaul
-
Patent number: 9006225Abstract: A pharmaceutical composition which includes a compound represented by the general formula (I): or a salt thereof, and a pharmaceutically acceptable carrier, wherein the composition does not substantially contain a reducing sugar and/or a carrier containing a reducing sugar as an ingredient as the pharmaceutically acceptable carrier, or when the composition contains a reducing sugar and/or a carrier containing a reducing sugar as an ingredient as the pharmaceutically acceptable carrier, contact of the reducing sugar and the compound represented by the general formula (I) or a salt thereof is eliminated.Type: GrantFiled: January 16, 2009Date of Patent: April 14, 2015Assignee: Asahi Kasei Pharma CorporationInventor: Kazumi Suzuki
-
Patent number: 8952137Abstract: A method is provided for producing soluble thrombomodulin substantially not containing a denatured product of the soluble thrombomodulin that is generated under acidic conditions, which comprises: subjecting the soluble thrombomodulin-containing material to an anion exchanger or hydroxyapatite; and carrying out linear gradient elution, stepwise gradient elution, or gradient elution in which linear gradient elution is combined with stepwise gradient elution under separation conditions in which the denatured product of the soluble thrombomodulin can be separated, wherein the gradient is a salt concentration gradient, so as to obtain an elution fraction containing soluble thrombomodulin that does not substantially contain the denatured product of the soluble thrombomodulin, either (a) after the position of a fraction has previously been confirmed, or (b) while confirming the elution fraction.Type: GrantFiled: July 25, 2012Date of Patent: February 10, 2015Assignee: Asahi Kasei Pharma CorporationInventor: Susumu Ohigashi
-
Patent number: 8772239Abstract: A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient.Type: GrantFiled: November 14, 2012Date of Patent: July 8, 2014Assignee: Asahi Kasei Pharma CorporationInventors: Kazuhisa Tsuruta, Yoshikazu Aoki, Yutaka Osawa, Inder Kaul
-
Patent number: 8772327Abstract: A compound represented by the following general formula (1) or a salt thereof, which has superior inhibitory activity against type 4 PLA2, and thus has prostaglandin and/or leucotriene production suppressing action [X represents a halogen atom, an alkyl group which may be substituted, or the like, Y represents hydrogen atom or an alkyl group which may be substituted, and Z represents hydrogen atom or an alkyl group which may be substituted].Type: GrantFiled: October 17, 2012Date of Patent: July 8, 2014Assignee: Asahi Kasei Pharma CorporationInventors: Kohei Morita, Hiroshi Kuriyama, Kosuke Tanaka
-
Patent number: 8664243Abstract: (S)-1-(4-Chloro-5-isoquinolinesulfonyl)-3-(methylamino)pyrrolidine monohydrochloride and a crystal thereof, and a crystal of the aforementioned monohydrochloride having a major peak or peaks at one or more positions selected from the group consisting of positions where 2?s are about 13.9°, 21.5°, 21.7°, 22.4°, 22.8°, 24.5° and 35.0° in a powder X-ray diffraction spectrum, which have excellent properties as active ingredient of a medicament for prophylactic and/or therapeutic treatment of glaucoma and the like.Type: GrantFiled: June 27, 2012Date of Patent: March 4, 2014Assignee: Asahi Kasei Pharma CorporationInventors: Hitoshi Kida, Koki Matsubara, Shunsuke Kaneko
-
Patent number: 8476259Abstract: Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing pulmonary arterial hypertension and/or stable angina. More particularly, aspects of the present invention are related to therapeutic combinations comprising a Rho-kinase inhibitor, such as fasudil, and one or more additional compounds selected from the group consisting of prostacyclins, such as iloprost, endothelin receptor antagonists, PDE inhibitors, calcium channel blockers, 5-HT2A antagonists, such as sarpogrelate, selective serotonin reuptake inhibitors, such as fluoxetine, statins, and vascular remodeling modulators, such as Gleevec.Type: GrantFiled: September 12, 2012Date of Patent: July 2, 2013Assignee: Asahi Kasei Pharma CorporationInventor: Benson Fong
-
Patent number: 8415372Abstract: A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G1 represents hydrogen atom, chlorine atom, hydroxyl group, an alkoxy group, or amino group; G2 represents a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, and the like; G3 represents hydrogen atom, a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, and the like; G4 represents hydroxyl group, or —N(R1)(R2) (R1 and R2 represent hydrogen atom, an alkyl group, an aralkyl group, an alkenyl group, an alkynyl group, or a saturated heterocyclic group); G5 is a substituent on a ring-constituting carbon atom of A, and represents hydrogen atom, fluorine atom, or an alkyl group] or a salt thereof, or a derivative thereof that is a prodrug, which potently inhibits Rho kinase.Type: GrantFiled: February 27, 2007Date of Patent: April 9, 2013Assignee: Asahi Kasei Pharma CorporationInventors: Rintaro Yamada, Minoru Seto
-
Patent number: 8334314Abstract: A compound represented by the following general formula (1) or a salt thereof, which has superior inhibitory activity against type 4 PLA2, and thus has prostaglandin and/or leucotriene production suppressing action [X represents a halogen atom, an alkyl group which may be substituted, or the like, Y represents hydrogen atom or an alkyl group which may be substituted, and Z represents hydrogen atom or an alkyl group which may be substituted].Type: GrantFiled: April 27, 2009Date of Patent: December 18, 2012Assignee: Asahi Kasei Pharma CorporationInventors: Kohei Morita, Hiroshi Kuriyama, Kosuke Tanaka
-
Patent number: 8304443Abstract: Compounds represented by the Formula (A-1) and the Formula (1) or salt thereof are provided. The compounds represented by the Formula (A-1) and the Formula (1) or salt thereof have a ?3 adrenergic receptor agonist activity, and therefore are useful as an agent for the prevention and treatment of diabetes, obesity, hyperlipidemia, depression, biliary stone, a disorder derived from hyperactivity of biliary tract, a disorder derived from hyperactivity of digestive tract, interstitial cystitis, overactive bladder, urinary incontinence or a disorder derived from decreased tear secretion, etc.Type: GrantFiled: September 29, 2009Date of Patent: November 6, 2012Assignee: Asahi Kasei Pharma CorporationInventors: Seiji Nakano, Akifumi Morimoto, Yasuhiro Wada